Novavax, Inc. (NASDAQ:NVAX) Given Consensus Recommendation of “Hold” by Brokerages

Novavax, Inc. (NASDAQ:NVAX) has been assigned an average recommendation of “Hold” from the nine ratings firms that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $11.3333.

Several equities analysts have recently commented on the stock. HC Wainwright upped their price objective on shares of Novavax from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday. Weiss Ratings restated a “sell (d+)” rating on shares of Novavax in a report on Saturday. Cantor Fitzgerald assumed coverage on shares of Novavax in a report on Friday. They issued an “overweight” rating and a $18.00 price objective on the stock. Finally, Bank of America restated an “underperform” rating and issued a $7.00 price objective (down from $9.00) on shares of Novavax in a report on Wednesday, August 20th.

Novavax Stock Up 1.9%

Shares of NASDAQ NVAX opened at $8.52 on Monday. Novavax has a 12-month low of $5.01 and a 12-month high of $11.55. The stock has a market cap of $1.38 billion, a PE ratio of 3.74, a P/E/G ratio of 0.13 and a beta of 2.74. The company has a current ratio of 2.36, a quick ratio of 2.34 and a debt-to-equity ratio of 5.93. The company has a 50-day moving average of $8.40 and a 200 day moving average of $7.44.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.69. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The company had revenue of $239.24 million during the quarter, compared to analysts’ expectations of $149.19 million. During the same quarter in the prior year, the company earned $0.99 EPS. Novavax’s revenue was down 42.4% compared to the same quarter last year. As a group, sell-side analysts predict that Novavax will post -1.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Novavax

Several large investors have recently made changes to their positions in NVAX. State of Wyoming acquired a new position in shares of Novavax in the 2nd quarter worth approximately $52,000. Signaturefd LLC lifted its holdings in Novavax by 47.2% during the 2nd quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 3,122 shares in the last quarter. Vise Technologies Inc. acquired a new stake in Novavax during the 2nd quarter worth approximately $70,000. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Novavax during the 1st quarter worth approximately $71,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Novavax during the 2nd quarter worth approximately $72,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.